Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Article Title: Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data

doi: 10.1177/13524585241240398

Figure Lengend Snippet: Average number of relapses and percent reductions in emulated clinical trials.

Article Snippet: Claims Dataset Clinformatics ® Data Mart (CDM) PharMetrics ® Plus for Academics Number of Cases 483 301 Number of Controls 1500 1000 Relapse Identification Algorithm Marriott et al. Chastek et al. Marriott et al. Chastek et al. Average relapses in cases [95% CI] 0.055 [0.048, 0.062] 0.436 [0.422, 0.450] 0.175 [0.137, 0.213] 0.483 [0.466, 0.519] Average relapses in controls [95% CI] 0.132 [0.125, 0.140] 0.501 [0.480, 0.521] 0.202 [0.186, 0.217] 0.536 [0.517, 0.555] Annualized relapse rate (ARR) in cases 0.028 0.218 0.087 0.242 Annualized relapse rate (ARR) in controls 0.066 0.251 0.101 0.268 Percent Reduction 58.3% 12.9% 13.4% 9.89% Average E-Value [95% CI] 5.24 [3.52, 8.97] 1.86 [1.73, 1.99] 4.49 [2.58, 6.41] 2.19 [1.93, 2.46] Open in a separate window Average number of relapses and percent reductions in emulated clinical trials.

Techniques: